Accordingly, patients with a relatively low proportion of DP pTemra (<6%) demonstrated twice more CD8+ TILs than patients with a high proportion of DP pTemra (>6%; figure 6E), allowing us to predict the number of CD8+ TILs simply by analyzing DP Temra cells in the blood of patients with NSCLC. This evidence concerns the gene CD8A and non-small cell lung carcinoma.